Michael Spinner, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #A453
San Francisco CA 94117
Phone415-353-8398
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford University Medical Center, Palo Alto, CA06/2020Hematology/Oncology
    Stanford University Medical Center, Palo Alto, CA06/2016Internal Medicine
    Vanderbilt University School of Medicine, Nashville, TNMD05/2014Medicine
    Emory University, Atlanta, GABA05/2009Music (Classical Guitar)
    Collapse Awards and Honors
    Conquer Cancer Foundation2020Young Investigator Award
    Stanford Hematology/Oncology Fellowship Program2020Scientific Merit Award
    American Society of Hematology2018ASH Clinical Research Training Institute
    American Society of Hematology2016ASH Abstract Achievement Award
    Stanford Internal Medicine Residency Program2014Julian Wolfsohn Award for Outstanding Performance in Internal Medicine
    Stanford University School of Medicine2014Stanford Society of Physician Scholars
    Vanderbilt University School of Medicine2014Alpha Omega Alpha
    Vanderbilt University School of Medicine2014Rudolph H. Kampmeier Prize in Clinical Medicine
    National Institute of Allergy and Infectious Diseases2014NIAID Merit Award
    National Institutes of Health2012NIH Medical Research Scholars Program
    Emory University2008Phi Beta Kappa
    Emory University2007William H. Murdy Natural Science and Mathematics Award

    Collapse Overview 
    Collapse Overview
    I am a hematologist/oncologist and care for patients with blood cancers with a particular focus on Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and Waldenstrom macroglobulinemia. I have a particular interest in immunotherapy, targeted therapies, stem cell transplantation, and CAR T-cell therapy, in which a patient’s T cells are engineered to target and kill cancer cells.

    My research focuses on novel immunotherapy approaches to treat lymphoma and personalized medicine, tailoring treatment to individual patients based on their disease characteristics and tumor genetics. I am a co-investigator on clinical trials evaluating new immunotherapies to treat lymphoma and collaborate with leading scientists on identifying biomarkers to predict which patients may benefit from certain treatments.

    I received my medical degree from Vanderbilt University and completed my internal medicine residency and hematology/oncology fellowship from Stanford University under the mentorship of Dr. Ranjana Advani. I serve on the Hodgkin lymphoma guidelines committee for the National Comprehensive Cancer Network.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Emerging immunotherapies in the Hodgkin Lymphoma Armamentarium. Expert Opin Emerg Drugs. 2024 Apr 27. Spinner MA, Advani RH. PMID: 38676917.
      View in: PubMed   Mentions:
    2. Cell Therapy: Actionable Takeaways from the 2023 Precision Oncology Summit Session. Int J Cancer Care Deliv. 2024. Abrams H, Abuali I, Khan AM, Riano I, Allen G, Spinner MA, Komanduri KV.
    3. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms. Leuk Res. 2024 01; 136:107433. Khanna V, Lu R, Kumar J, Molina A, Stehr H, Spiteri E, Spinner M, Silva O, Fernandez-Pol S, Tan B, Greenberg PL. PMID: 38154193.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood Adv. 2023 12 12; 7(23):7295-7303. Desai SH, Spinner MA, Evens AM, Sykorova A, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Chang C, Michalka J, Ansell SM, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Wagner-Johnston N, Arai S, Nowakowski GS, Mocikova H, Jagadeesh D, Blum KA, Diefenbach C, Iyengar S, Rappazzo KC, Baidoun F, Choi Y, Prochazka V, Advani RH, Micallef I. PMID: 37729621; PMCID: PMC10711178.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Long-term Survivors and Failures of CAR-T Therapy for Lymphoma: Is there a Role for Allogeneic Transplantation After the CAR-T Crash? Transplant Cell Ther. 2023 Dec; 29(12):725-726. Spinner MA, Komanduri KV. PMID: 38035887.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv. 2023 11 14; 7(21):6630-6638. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. PMID: 37595053; PMCID: PMC10628810.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy. Cancers (Basel). 2023 Sep 11; 15(18). Randall MP, Spinner MA. PMID: 37760478; PMCID: PMC10526852.
      View in: PubMed   Mentions: 2  
    8. Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy. Eur J Nucl Med Mol Imaging. 2023 09; 50(11):3349-3353. Banerjee R, Wang V, Huang CY, Pandita D, Leonard MK, LaRue S, Ahmadi M, Kaplan L, Ai WZ, Fakhri B, Spinner M, Seshadri MR, Pampaloni MH, Andreadis CB. PMID: 37300573; PMCID: PMC10853015.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. 2023 06 01; 141(22):2727-2737. Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, Frank MJ, Johnston LJ, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shiraz P, Shizuru JA, Weng WK, Binkley MS, Hoppe RT, Advani RH, Arai S. PMID: 36857637.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023 03; 98(3):464-471. Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, Jagadish D, Orellana-Noia V, Diefenbach C, Iyenger S, Rappazzo KC, Mishra R, Choi Y, Nowakowski GS, Advani RH, Micallef IN. PMID: 36629030.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. Oncology (Williston Park). 2022 01 20; 36(1):51-58. Spinner MA, Advani RH. PMID: 35089671.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    12. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 01 20; 139(3):413-423. Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. PMID: 34570876; PMCID: PMC8777199.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    13. Increased double-negative αβ+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease. Haematologica. 2022 01 01; 107(1):347-350. Brar N, Spinner MA, Baker MC, Advani RH, Natkunam Y, Lewis DB, Silva O. PMID: 34474549; PMCID: PMC8719087.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    14. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clin Lymphoma Myeloma Leuk. 2022 07; 22(7):e435-e442. Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, Allen P, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Bailey NA, Pagel JM, Ramchandren R. PMID: 35093285.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2022 01; 57(1):106-112. Dworkin ML, Jiang AL, Von Eyben R, Spinner MA, Advani RH, Lowsky R, Hiniker SM, Hoppe RT. PMID: 34671121.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021 07 22; 138(3):213-220. Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, Shustov AR, Horwitz SM, Hitz F, Cabrera ME, Dlouhy I, Vassallo J, Pileri SA, Inghirami G, Montoto S, Vitolo U, Radford J, Vose JM, Federico M. PMID: 34292324; PMCID: PMC8493974.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    17. Pulmonary Manifestations of GATA2 Deficiency. Chest. 2021 10; 160(4):1350-1359. Marciano BE, Olivier KN, Folio LR, Zerbe CS, Hsu AP, Freeman AF, Filie AC, Spinner MA, Sanchez LA, Lovell JP, Parta M, Cuellar-Rodriguez JM, Hickstein DD, Holland SM. PMID: 34089740; PMCID: PMC8546236.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    18. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. Arch Pathol Lab Med. 2021 06 01; 145(6):753-758. Menke JR, Spinner MA, Natkunam Y, Warnke RA, Advani RH, Gratzinger DA. PMID: 32991677.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    19. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. PMID: 33710337; PMCID: PMC7993097.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    20. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. PMID: 33658659.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    21. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2020 10 13; 4(19):4640-4647. Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, Yeung J, Spinner MA, Lunning M, Inghirami G, Moskowitz A, Galasso N, Ganesan N, van der Weyden C, Ruan J, Prince HM, Trotman J, Advani R, Dogan A, Horwitz S. PMID: 33002132; PMCID: PMC7556143.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    22. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist. 2020 10; 25(10):878-885. Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. PMID: 32720734; PMCID: PMC7543382.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    23. Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Adv. 2020 06 23; 4(12):2768-2778. Spinner MA, Aleshin A, Santaguida MT, Schaffert SA, Zehnder JL, Patterson AS, Gekas C, Heiser D, Greenberg PL. PMID: 32569379; PMCID: PMC7322964.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    24. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 10; 191(1):44-51. Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. PMID: 32430944.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    25. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist. 2020 06; 25(6):e993-e997. Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. PMID: 32275786; PMCID: PMC7288660.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    26. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Adv. 2019 08 27; 3(16):2454-2464. Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, Lowsky R. PMID: 31427277; PMCID: PMC6712526.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    27. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. J Clin Oncol. 2019 08 20; 37(24):2105-2119. Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. PMID: 31157579.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    28. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):200-206. Spinner MA, Advani RH. PMID: 30504311; PMCID: PMC6245987.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    29. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2019 01; 184(1):17-29. Spinner MA, Varma G, Advani RH. PMID: 30485408.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    30. Novel Approaches in Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 Oct; 32(5):875-890. Spinner MA, Varma G, Advani RH. PMID: 30190025.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Blood Adv. 2018 07 10; 2(13):1547-1550. Spinner MA, Advani RH, Hoppe RT, Lowsky R, Muffly LS. PMID: 29970391; PMCID: PMC6039652.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    32. New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? Am Soc Clin Oncol Educ Book. 2018 May 23; 38:626-636. Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C. PMID: 30231319.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv. 2017 Jul 25; 1(17):1347-1357. Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR. PMID: 29296777; PMCID: PMC5727975.
      View in: PubMed   Mentions: 4     Fields:    
    34. GATA2 deficiency underlying severe blastomycosis and fatal herpes simplex virus-associated hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2016 Feb; 137(2):638-40. Spinner MA, Ker JP, Stoudenmire CJ, Fadare O, Mace EM, Orange JS, Hsu AP, Holland SM. PMID: 26395816; PMCID: PMC4747814.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    35. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014 Feb 06; 123(6):809-21. Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM. PMID: 24227816; PMCID: PMC3916876.
      View in: PubMed   Mentions: 316     Fields:    Translation:Humans
    36. What does the duty to warn require? Am J Bioeth. 2013; 13(10):62-3. Shah SK, Hull SC, Spinner MA, Berkman BE, Sanchez LA, Abdul-Karim R, Hsu AP, Claypool R, Holland SM. PMID: 24024817; PMCID: PMC4816221.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    37. Duodenal histoplasmosis presenting with upper gastrointestinal bleeding in an AIDS patient. Case Rep Gastrointest Med. 2012; 2012:515872. Spinner MA, Paulin HN, Wester CW. PMID: 23091745; PMCID: PMC3471405.
      View in: PubMed   Mentions: 7  
    Michael's Networks
    Concepts (141)
    Derived automatically from this person's publications.
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _